Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: First-line treatment of advanced renal cell carcinoma (RCC) Age: Adult Condition: Combination with nivolumab |
Dose: Tablet – 40 mg Frequency: once daily Note: Administered in combination with nivolumab 240 mg every 2 weeks or 480 mg every 4 weeks. |
|
Indication: Advanced renal cell carcinoma (RCC) Age: Adult Condition: Single agent |
Dose: Tablet – 60 mg Frequency: once daily Note: Continue until disease progression or unacceptable toxicity occurs. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Differentiated Thyroid Cancer Age: Pediatric (greater than 12 years) Condition: Locally advanced or metastatic, progressed following prior VEGFR-targeted therapy, and radioactive iodine-refractory or ineligible |
Dose: Tablet – 40 mg Frequency: once daily Note: by mouth (oral). Continue until disease progression or unacceptable toxicity. This indication and dosage is specific for tablet formulation. Do not use interchangeably with the capsule formulation due to different bioequivalence. |
|
Indication: Differentiated Thyroid Cancer Age: Pediatric (greater than 12 years) Condition: Locally advanced or metastatic, progressed following prior VEGFR-targeted therapy, and radioactive iodine-refractory or ineligible |
Dose: Tablet – 60 mg Frequency: once daily Note: by mouth (oral). Continue until disease progression or unacceptable toxicity. This indication and dosage is specific for tablet formulation. Do not use interchangeably with the capsule formulation due to different bioequivalence. |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment Mild-to-moderate (CrCl greater than 30 mL/min) |
Dose: No dosage adjustment necessary Note: Renal impairment Mild-to-moderate (CrCl greater than 30 mL/min): No dosage adjustment necessary |
|
Condition: Renal impairment Severe (CrCl less than 30 mL/min) |
Dose: No experience Note: Renal impairment Severe (CrCl less than 30 mL/min): No experience |
Administration
- Take on empty stomach
- Take at least 1 hour before or 2 hours after meals
Side Effect
- AST, ALT increased (86%)
- Diarrhea (63%)
- Hypertension, treatment-emergent (61%)
- Increased TSH (57%)
- Lymphopenia (53%)
- ALP increased (52%)
- Hypocalcemia (52%)
- Stomatitis (51%)
- Palmar-plantar erythrodysesthesia syndrome (50%)
- Weight decreased (48%)
- Appetite decreased (46%)
- Nausea (43%)
- Fatigue (41%)
- Oral pain (36%)
- Neutropenia (35%)
- Thrombocytopenia (35%)
- Dysgeusia (34%)
- Hair color changes, depigmentation, graying (34%)
- Hypertension (33%)
- Hypophosphatemia (28%)
- Constipation (27%)
- Abdominal pain (27%)
- Hypobilirubinemia (25%)
- Vomiting (24%)
- Asthenia (21%)
- Dysphonia (20%)
- Rash (19%)
- Dry skin (19%)
- Hypomagnesemia (19%)
- Hypokalemia (18%)
- Headache (18%)
- Alopecia (16%)
- Dizziness (14%)
- Arthralgia (14%)
- Palmar-plantar erythrodysesthesia syndrome, Grade 3 or 4 (13%)
- Dysphagia (13%)
- Muscle spasms (12%)
- Dyspepsia (11%)
- Erythema (11%)
- Hyponatremia (10%)
- Hemorrhoids (9%)
- Musculoskeletal chest pain (9%)
- Anxiety (9%)
- Paresthesia (7%)
- Peripheral sensory neuropathy (7%)
- Dehydration (7%)
- Hyperkeratosis (7%)
- Hypotension (7%)
- Venous thromboembolism (6%)
- Peripheral neuropathy (5%)
- Non-GI fistula (4%)
- GI perforation (3%)
- Arterial thromboembolism (2%)
- Proteinuria (2%)
- GI fistula (1%)
- Osteonecrosis of the jaw (1%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Strong CYP3A4 enzyme inhibitors (e.g. ketoconazole, itraconazole)
|
Increased plasma concentration
|
|
Strong CYP3A4 enzyme inducers (e.g. rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine)
|
Decreased plasma concentration
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
History of Haemorrhage or Haemoptysis
|
Risk of severe bleeding
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store Cabozantinib at room temperature 20°C to 25°C
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.